TCI Wealth Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

TCI Wealth Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-112	Closed	-$16K	–	2737
2022 Q2	$16K	Sell	112 -12	-10%	-$1.53K	﹤0.01%	754
2022 Q1	$15K	Buy	124 +46	+59%	+$5.74K	﹤0.01%	858
2021 Q4	$11K	Sell	78 -14	-15%	-$1.78K	﹤0.01%	1132
2021 Q3	$13K	Buy	92 +14	+18%	+$1.75K	﹤0.01%	951
2021 Q2	$8K	Buy	78 +38	+95%	+$3.08K	﹤0.01%	1168
2021 Q1	$3K	Buy	+40	New	+$3.23K	﹤0.01%	1638

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TCI Wealth Advisors's BHVN Position: Q3 2022 in Review

TCI Wealth Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 112 shares — an estimated $16K sold.

TCI Wealth Advisors first reported a position in BHVN in Q1 2021 and held it in 6 quarters. The position peaked at $16K in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

TCI Wealth Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
TCI Wealth Advisors sold 112 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $16K.
TCI Wealth Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021 and held it in 6 quarters.
TCI Wealth Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $16K in Q2 2022.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on TCI Wealth Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.